伏诺拉生 (Voquezna 14 Day Dualpak 20;500, Voquezna 14 Day Triplepak 20;500;500)

概览

Vonoprazan is a potassium-competitive acid blocker used in the treatment of acid-related disorders and as an adjunct to Helicobacter pylori eradication.

作用机制

Vonoprazan is a potassium-competitive acid blocker (PCAB) that inhibits the H, K-ATPase enzyme system in a potassium-competitive manner. Through this mechanism, vonoprazan suppresses basal and stimulated gastric acid secretion at the secretory surface of gastric parietal cells. Although both classes of drugs inhibit the H, K-ATPase, the mechanism of action of PCABs differs from that of proton-pump inhibitors (PPIs). PPIs form a covalent disulphide bond with a cysteine residue on the H, K-ATPase, which leads to the inactivation of the enzyme, while PCABs interfere with the binding of K to the H, K-ATPase.

适应症

Vonoprazan, in combination with amoxicillin and clarithromycin in a co-packaged product, is indicated for the treatment of Helicobacter pylori (H. pylori) infection in adults. Another co-packaged product with only vonoprazan and amoxicillin is also indicated for the treatment of H. pylori infection in adults.

• Duodenal Ulcer
• Gastric Ulcer
• Gastric or Duodenal Ulcers Caused by Low-dose Aspirin
• Helicobacter Pylori Infection
• Reflux Esophagitis (RE)
• Develop NSAID-induced gastric ulcers